¼¼°èÀÇ °ñ¹Ý ¿°Áõ¼º Áúȯ(PID) Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Pelvic Inflammatory Disease (PID) Treatment Global Market Report 2025
»óǰÄÚµå : 1720860
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,242,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,023,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,803,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°ñ¹Ý ¿°Áõ¼º Áúȯ(PID) Ä¡·á ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ³ôÀº ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ¼ºº´(STI) À¯º´·ü Áõ°¡, ¿©¼º »ý½Ä °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, °ñ¹Ý ¿°Áõ¼º Áúȯ(PID)¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¿ø°Ý ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ÀÇÁ¸µµ Áõ°¡, ¼ºº´ ¹ß»ý·ü Áõ°¡¿¡ ±âÀÎÇÑ °ÍÀ¸·Î º¼ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä Æ®·»µå¿¡´Â Çõ½ÅÀûÀÎ PID Ä¡·á Á¦Ç°, Áø´Ü ±â¼úÀÇ ¹ßÀü, °³ÀÎ ¸ÂÃãÇü Ä¡·áÀÇ Çõ½Å, ÷´Ü À̹Ì¡ ±â¼ú ¹× ±âŸ ±â¼ú ¹ßÀüÀÌ Æ÷ÇԵ˴ϴÙ.

¼ºº´(STI)ÀÇ À¯º´·ü Áõ°¡´Â °ñ¹Ý ¿°Áõ¼º Áúȯ(PID) Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼ºº´Àº ÁÖ·Î Áú, Ç×¹® ¶Ç´Â ±¸°­ ¼º±³¸¦ Æ÷ÇÔÇÑ ¼ºÀû Á¢ÃËÀ» ÅëÇØ ÀüÆÄµÇ´Â ¹ÚÅ׸®¾Æ, ¹ÙÀÌ·¯½º ¶Ç´Â ±â»ýÃæ¿¡ ÀÇÇÑ °¨¿°ÀÔ´Ï´Ù. ¼ºº´ À¯º´·üÀÇ Áõ°¡´Â À§ÇèÇÑ ¼ºÇàÀ§, ¹«¹æºñ ¼º°ü°è, ÀÎ½Ä ºÎÁ·, °Ë»ç ¹× Ä¡·á Áö¿¬°ú °°Àº ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. Ç×»ýÁ¦¸¦ »ç¿ëÇÏ¿© °¨¿°À» ÀÏÀ¸Å°´Â ¹ÚÅ׸®¾Æ¸¦ Á¦°ÅÇÏ°í ¸¸¼º °ñ¹ÝÅë ¹× ºÒÀÓ°ú °°Àº ÇÕº´ÁõÀ» ¿¹¹æÇϸç Àç¹ß À§ÇèÀ» ÁÙÀ̱â À§ÇØ Ç×»ýÁ¦¸¦ »ç¿ëÇÏ´Â PID Ä¡·á´Â ¼º¸Å°³°¨¿°º´ °ü¸®¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 10¿ù ¿µ±¹ º¸°Ç¾Èº¸±¹(UKHSA)ÀÇ º¸°í¼­¿¡ µû¸£¸é 2023³â ¿µ±¹¿¡¼­ 6,008°ÇÀÇ »õ·Î¿î HIV Áø´ÜÀÌ ¹ß»ýÇÏ¿© 2022³âÀÇ 3,975°Ç¿¡ ºñÇØ 51% Áõ°¡Çß´Ù°í ÇÕ´Ï´Ù. µû¶ó¼­ ¼ºº´ À¯º´·üÀÇ Áõ°¡´Â PID Ä¡·á ½ÃÀåÀÇ È®ÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

°ñ¹Ý ¿°Áõ¼º Áúȯ(PID) Ä¡·á ½ÃÀå¿¡ ÁøÃâÇÑ ±â¾÷µéÀº Ä¡·á È¿´ÉÀ» ³ôÀ̰í Áú ³» ¹Ì»ý¹° ±ÕÇüÀ» ȸº¹Çϸç PID ȯÀÚÀÇ °¨¿° Àç¹ßÀ» ÁÙÀ̱â À§ÇØ ÇÁ·Î¹ÙÀÌ¿Àƽ½º º¸ÃæÁ¦¿Í °°Àº Çõ½ÅÀûÀÎ Á¦Çü °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÇÁ·Î¹ÙÀÌ¿Àƽ º¸ÃæÁ¦´Â Àå°ú Áú ³» ¹Ì»ý¹°ÀÇ °Ç°­ÇÑ ±ÕÇüÀ» À¯ÁöÇϰųª ȸº¹ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â À¯ÀÍÇÑ »ì¾ÆÀÖ´Â ¹ÚÅ׸®¾Æ ¶Ç´Â È¿¸ð¸¦ ÇÔÀ¯Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 11¿ù Àεµ¿¡ º»»ç¸¦ µÐ Á¦¾à ȸ»çÀÎ Lee Health DomainÀº Áú °Ç°­ Áö¿øÀ» ¸ñÀûÀ¸·Î ÇÏ´Â ÇÁ·Î¹ÙÀÌ¿Àƽ º¸ÃæÁ¦ÀÎ V-FerinÀ» Ãâ½ÃÇß½À´Ï´Ù. ¶ôÅä¹Ù½Ç·¯½º ¾Æ½ÃµµÇʷ罺, ¶ôÅäÆä¸° ÆéŸÀ̵å, Å©·£º£¸® ÃßÃâ¹°·Î Á¦Á¶µÈ V-FerinÀº õ¿¬ ¹Ì»ý¹° ±ºÁýÀ» º¹¿øÇÏ°í ¼¼±Õ¼º Áú¿° ¹× È¿¸ð °¨¿°°ú °°Àº ÀϹÝÀûÀÎ Áú °¨¿°À» ¿¹¹æÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¿©¼ºÀÇ ¾à 25-30%°¡ ÀÌ·¯ÇÑ ÁúȯÀÇ ¿µÇâÀ» ¹Þ°í ÀÖÀ¸¸ç, Ä¡·áÇÏÁö ¾Ê°í ¹æÄ¡ÇÒ °æ¿ì PID·Î À̾îÁú ¼ö Àֱ⠶§¹®¿¡ V-FerinÀº °Ç°­À» °³¼±Çϰí ÇÕº´ÁõÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Pelvic inflammatory disease (PID) treatment involves the medical management of infections affecting the female reproductive organs, typically caused by sexually transmitted bacteria such as Chlamydia trachomatis and Neisseria gonorrhoeae. The goal of treatment is to eliminate the infection, alleviate symptoms, and prevent complications such as infertility, chronic pelvic pain, and ectopic pregnancy.

The main types of PID treatment include antibiotic therapy, surgery, pain management, and hormonal therapy. Antibiotic therapy involves using antibiotics to treat bacterial infections by killing or inhibiting the growth of bacteria. It can be administered orally, intravenously, or intramuscularly, and PID treatment is available in hospitals, clinics, and home care settings.

The pelvic inflammatory disease (PID) treatment market research report is one of a series of new reports from The Business Research Company that provides pelvic inflammatory disease (PID) treatment market statistics, including the pelvic inflammatory disease (PID) treatment industry global market size, regional shares, competitors with the pelvic inflammatory disease (PID) treatment market share, detailed pelvic inflammatory disease (PID) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the pelvic inflammatory disease (PID) treatment industry. This pelvic inflammatory disease (PID) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pelvic inflammatory disease (PID) treatment market size has grown strongly in recent years. It will grow from $4.49 billion in 2024 to $4.75 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the growing adoption of telemedicine, the rising incidence of sexually transmitted infections (STIs), increasing awareness of pelvic inflammatory disease (PID), and higher healthcare expenditure.

The pelvic inflammatory disease (PID) treatment market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth during the forecast period can be attributed to the increasing prevalence of sexually transmitted infections (STIs), rising awareness regarding women's reproductive health, growing awareness of pelvic inflammatory disease (PID), increasing reliance on telehealth services, and a rising incidence of STIs. Key trends expected during this period include innovative PID treatment products, advancements in diagnostic technologies, innovations in personalized treatment, advanced imaging techniques, and other technological advancements.

The rising prevalence of sexually transmitted infections (STIs) is expected to drive the growth of the pelvic inflammatory disease (PID) treatment market. STIs are infections caused by bacteria, viruses, or parasites that are primarily spread through sexual contact, including vaginal, anal, or oral sex. The increasing prevalence of STIs is attributed to factors such as risky sexual behaviors, unprotected sex, lack of awareness, and delayed testing and treatment. PID treatment is crucial for managing STIs, as it involves the use of antibiotics to eliminate the bacteria causing the infection, preventing complications such as chronic pelvic pain and infertility, and reducing the risk of recurrent infections. For example, in October 2024, a report from the UK Health Security Agency (UKHSA) revealed that in 2023, England recorded 6,008 new HIV diagnoses, marking a 51% increase compared to 3,975 in 2022. Therefore, the growing prevalence of STIs is driving the expansion of the PID treatment market.

Companies operating in the pelvic inflammatory disease (PID) treatment market are focusing on developing innovative formulations, such as probiotic supplements, to enhance treatment efficacy, restore vaginal microbiota balance, and reduce the recurrence of infections in PID patients. Probiotic supplements contain beneficial live bacteria or yeasts that help maintain or restore a healthy balance of the gut and vaginal microbiota. For example, in November 2024, Lee Health Domain, an India-based pharmaceutical company, launched V-Ferin, a probiotic supplement aimed at supporting vaginal health. Formulated with Lactobacillus acidophilus, lactoferrin peptide, and cranberry extract, V-Ferin seeks to restore the natural microbiome and prevent common vaginal infections such as bacterial vaginosis and yeast infections. With approximately 25-30% of women affected by these conditions, which can lead to PID if left untreated, V-Ferin offers an innovative solution to improve health and prevent complications.

In February 2022, Mankind Pharma Limited, an India-based pharmaceutical company, acquired Panacea Biotec Limited (PBL) for $212.88 million. This acquisition strengthens Mankind Pharma's position in the chronic and transplant business by integrating well-researched formulations and leveraging advanced technology and niche expertise, while retaining Panacea Biotec's sales and marketing team to ensure seamless business operations and market expansion. Panacea Biotec Limited is an India-based biotechnology company that develops, manufactures, and commercializes pharmaceuticals, vaccines, and biosimilars for various diseases, including pelvic inflammatory disease (PID).

Major players in the pelvic inflammatory disease (PID) treatment market are Pfizer Inc., Bayer AG, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Mayne Pharma Group Limited, Saphnix Lifesciences, Aristo Pharmaceuticals Pvt. Ltd., Zydus Cadila Healthcare Ltd., and Amagen India Life Sciences.

North America was the largest region in the pelvic inflammatory disease (PID) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pelvic inflammatory disease (PID) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pelvic inflammatory disease (PID) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pelvic inflammatory disease (PID) treatment market consists of revenues earned by entities by providing services such as medication therapy, pain management, and hospital and clinic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pelvic inflammatory disease (PID) treatment market includes sales of antibiotics, pain relievers, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pelvic Inflammatory Disease (PID) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pelvic inflammatory disease (pid) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pelvic inflammatory disease (pid) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pelvic inflammatory disease (pid) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pelvic Inflammatory Disease (PID) Treatment Market Characteristics

3. Pelvic Inflammatory Disease (PID) Treatment Market Trends And Strategies

4. Pelvic Inflammatory Disease (PID) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pelvic Inflammatory Disease (PID) Treatment Growth Analysis And Strategic Analysis Framework

6. Pelvic Inflammatory Disease (PID) Treatment Market Segmentation

7. Pelvic Inflammatory Disease (PID) Treatment Market Regional And Country Analysis

8. Asia-Pacific Pelvic Inflammatory Disease (PID) Treatment Market

9. China Pelvic Inflammatory Disease (PID) Treatment Market

10. India Pelvic Inflammatory Disease (PID) Treatment Market

11. Japan Pelvic Inflammatory Disease (PID) Treatment Market

12. Australia Pelvic Inflammatory Disease (PID) Treatment Market

13. Indonesia Pelvic Inflammatory Disease (PID) Treatment Market

14. South Korea Pelvic Inflammatory Disease (PID) Treatment Market

15. Western Europe Pelvic Inflammatory Disease (PID) Treatment Market

16. UK Pelvic Inflammatory Disease (PID) Treatment Market

17. Germany Pelvic Inflammatory Disease (PID) Treatment Market

18. France Pelvic Inflammatory Disease (PID) Treatment Market

19. Italy Pelvic Inflammatory Disease (PID) Treatment Market

20. Spain Pelvic Inflammatory Disease (PID) Treatment Market

21. Eastern Europe Pelvic Inflammatory Disease (PID) Treatment Market

22. Russia Pelvic Inflammatory Disease (PID) Treatment Market

23. North America Pelvic Inflammatory Disease (PID) Treatment Market

24. USA Pelvic Inflammatory Disease (PID) Treatment Market

25. Canada Pelvic Inflammatory Disease (PID) Treatment Market

26. South America Pelvic Inflammatory Disease (PID) Treatment Market

27. Brazil Pelvic Inflammatory Disease (PID) Treatment Market

28. Middle East Pelvic Inflammatory Disease (PID) Treatment Market

29. Africa Pelvic Inflammatory Disease (PID) Treatment Market

30. Pelvic Inflammatory Disease (PID) Treatment Market Competitive Landscape And Company Profiles

31. Pelvic Inflammatory Disease (PID) Treatment Market Other Major And Innovative Companies

32. Global Pelvic Inflammatory Disease (PID) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pelvic Inflammatory Disease (PID) Treatment Market

34. Recent Developments In The Pelvic Inflammatory Disease (PID) Treatment Market

35. Pelvic Inflammatory Disease (PID) Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â